Marc Halperin

Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

Deborah P. Lubeck, Irene Agodoa, Nickhill Bhakta et al. · JAMA Network Open · 2019 · 321 citations · Full text

Public Health, Population Health Sciences, Clinical Epidemiology +16

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Alison Stopeck, Michael Rader, David Henry et al. · Journal of Medical Economics · 2012 · 70 citations

Pharmacy, Oncology, Pharmacoeconomics +17

The Generalized Data Model for clinical research

Mark D. Danese, Marc Halperin, Jennifer Duryea et al. · BMC Medical Informatics and Decision Making · 2019 · 35 citations · Full text

Computing, Biomedical Informatics, Health Informatics +15

Cost‐effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper‐limb post‐stroke spasticity in <scp>S</scp>cotland

Quan V. Doan, Pieter Gillard, Allison Brashear et al. · European Journal of Neurology · 2012 · 24 citations

Pharmacy, Pharmacoeconomics, Rehabilitation Medicine +17

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data

Mark D. Danese, Carolina Reyes, Michelle Gleeson et al. · Medical Care · 2016 · 24 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacoeconomic Modeling +13